Investigating B and CD4 T Cell Roles in Multiple Sclerosis
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
NA · University Hospital, Bordeaux · NCT04798651
This study is trying to understand how certain immune cells affect multiple sclerosis in patients to help find better treatments.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux (other) |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT04798651 on ClinicalTrials.gov |
What this trial studies
This study aims to identify the pathogenic properties of B and CD4 T cell subsets in patients with multiple sclerosis (MS) and clinically isolated syndrome (CIS). By analyzing blood and cerebro-spinal fluid samples from 150 participants, the researchers will explore the immune mechanisms involved in different forms of MS. The goal is to enhance understanding of disease progression and potentially develop new therapeutic strategies. The study is conducted at Bordeaux University Hospital, focusing on the immune response in MS patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with multiple sclerosis or clinically isolated syndrome.
Not a fit: Patients who are pregnant, breastfeeding, or unable to provide consent due to legal restrictions will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that more effectively halt the progression of multiple sclerosis.
How similar studies have performed: While there have been studies investigating immune cell roles in MS, this specific approach focusing on B and CD4 T cell subsets is novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * male or female subjects ; * Age ≥ 18 years; * subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome; * patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose; * affiliated to an health insurance system; * and who agree to participate in the study. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Where this trial is running
Bordeaux
- CHU de Bordeaux - service de neurologie — Bordeaux, France (RECRUITING)
Study contacts
- Principal investigator: Aurélie RUET, Prof — University Hospital, Bordeaux
- Study coordinator: Aurélie RUET, Prof
- Email: aurelie.ruet@chu-bordeaux.fr
- Phone: 05 56 79 55 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Clinically Isolated Syndrome, Autoimmune Diseases of the Nervous System, Multiple sclerosis, clinically isolated syndrome, lymphoid cells, CD4 T cells, B cells